Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy

BACKGROUND: Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Inflamm Bowel Dis
Hlavní autoři: Huang, Vivian W., Prosser, Connie, Kroeker, Karen I., Wang, Haili, Shalapay, Carol, Dhami, Neil, Fedorak, Darryl K., Halloran, Brendan, Dieleman, Levinus A., Goodman, Karen J., Fedorak, Richard N.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2015
Témata:
Original Clinical Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4450916/
https://ncbi.nlm.nih.gov/pubmed/25989340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000000376
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky